Patrice Herait

发表

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.

P. Hérait, J. Armand, G. Chabot, 1994, Journal of the National Cancer Institute.

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

S. Culine, P. Hérait, J. Armand, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

E. Van Cutsem, C. Punt, P. Hérait, 1999, European journal of cancer.